YMAB - Y-mAbs Therapeutics, Inc. Quarterly EPS earnings growth
Effective R&D control and sales transparency for Y-mAbs Therapeutics (YMAB) ensure stability amid the geopolitical neutrality of the biomed sector. The percentage change in quarterly EPS on GURU.Markets reflects this trend, where 65.60 represents the current level of the metric. Completing the picture are Thomas Gad's scientific approach to pediatric oncology treatment and the successful global rollout of innovative drugs.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_YMAB_-_Y-mAbs-Therapeutics_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "YmAbs (YMAB): Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 09/27/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns and data insights for company Y-mAbs Therapeutics (YMAB)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
- earnings and valuation multiples information:
YMAB - Final Profit|Future Profit Y-mAbs Therapeutics|YMAB - Market Price to Net Income Ratio|Forward P/E Multiple Y-mAbs Therapeutics|YMAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple YmAbs|YMAB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Y-mAbs Therapeutics|YMAB - Earnings per share for the trailing year|Quarterly EPS earnings growth ymabs.com|YMAB - Earnings growth in current year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics
- sales volume and revenue indicators:
Initial company analysis:YmAbs - YMAB
Y-mAbs Therapeutics (YMAB) is mitigating single-product dependency risks by developing a radioimmunotherapy portfolio to diversify revenue streams. Quarterly EPS growth measures earnings per share dynamics, reflecting the actual efficiency of business scaling. This metric determines the company's margin of safety during market shocks. It is critical for investors to track profit growth rates to assess fundamental stability. Analyzing the current quarterly EPS pace allows for the timely identification of fading growth momentum.
Direct competitors
ONC: Quarterly EPS earnings growth|Halozyme Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (Revolution Medicines Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Group AAPG|Quarterly EPS earnings growth CGON|Quarterly EPS earnings growth UroGen Pharma Ltd (URGN)|Quarterly EPS earnings growth BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth in annualized terms for the last twelve months|Erasca Oncology - Quarterly EPS earnings growth|DCTH: Year-over-year earnings per share growth for the last twelve months|AURA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months CADL|Year-over-year earnings per share growth for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|Year-over-year net earnings per share change for the last twelve months Citius Oncology|TuHURA Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Protara TARA|fatetherapeutics.com - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aadi Bioscience|TCRX: Quarterly EPS earnings growth|CSBR - Year-over-year net earnings per share change for the last twelve months|XBIT (XBiotech) - Quarterly EPS earnings growth|CVM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth OSTX|RADX (Radiopharm Theranostics Limited) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ARTV (Artiva Biotherapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months ANL|VERU: Year-over-year net earnings per share growth for the last 12 months|TPST - Quarterly EPS earnings growth|XLO (xiliotx.com) - Year-over-year net earnings per share growth for the last 12 months|Renovaro Biosciences - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months MURA|Year-over-year earnings per share growth for the last twelve months KAPA|Year-over-year net earnings per share growth for the last 12 months OKUR (OnKure Therapeutics Inc)|Quarterly EPS earnings growth CytoMed (GDTC)|Year-over-year earnings per share growth for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Tharimmune Corporation - Quarterly EPS earnings growth|ADVB (advanbiomed.com) - Year-over-year earnings per share growth for the last 12 months|Genprex, Inc (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI: Year-over-year earnings per share growth rate for the last twelve months|SBFM (Sunshine Biopharma, Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months XBIO (Xenetic Biosciences)|Quarterly EPS earnings growth SLRX|Purple Biotech - Year-over-year earnings per share growth for the last 12 months|American Oncology Network - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT - Year-over-year earnings per share growth for the last twelve months|Elevation Oncology (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Viracta Therapeutics (VIRX)|Year-over-year earnings per share growth for the last twelve months MorphoSys Corporation (MOR)|NAYA (NAYA Biosciences) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage)
